Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
Dose Escalation and
Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a
Trial complete and Phase 1b Disease Specific Expansion Cohorts Open
for Enrolment
LONDON - Dec. 12, 2024 - Avacta Therapeutics (AIM:
AVCT), a life sciences company
developing next generation peptide drug conjugates (PDC) targeting
powerful anti-tumor payloads directly to the tumor, today announces
the completion of the enrollment in the AVA6000 Phase 1a Dose
Escalation and Recommended Dose for Expansion (RDE) cohort, and the
opening of the Phase 1b disease-specific expansion cohorts
in the trial. Patient screening has
commenced.
The Phase 1b expansion cohorts
follow the encouraging preliminary results in the trial reported
earlier in 2024 demonstrating a favorable safety profile and
significant antitumor activity in patients with salivary gland
cancers (a subset of head and neck cancer) and high-grade soft
tissue sarcoma.
The Phase 1b cohorts will enroll
patients in three disease-specific cohorts including: (1) triple
negative breast cancer; (2) salivary gland cancer and (3) high
grade soft tissue sarcoma.
Updated data for the Phase 1 dose
escalation cohorts and the recommended dose for expansion cohort
will be presented in the first half of 2025.
Christina Coughlin, MD PhD, CEO of Avacta,
commented: "We are encouraged by the
anti-tumor activity observed in the Phase 1 dose escalation and RDE
cohorts of the trial and the expansion cohorts are designed to
build on that knowledge. Opening of the expansion cohorts
represents a significant milestone in the development of
FAP-Doxorubicin (AVA6000) in that we will now be able to assess the
activity in specific indications to better plan Phase 2
development."
For further information from Avacta
Group plc, please contact:
About the pre|CISION® Platform
The
pre|CISION® platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for
fibroblast activation protein (FAP) which is upregulated in most
solid tumors compared with healthy tissues. The
pre|CISION® platform harnesses this tumor specific protease to cleave
pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and
reducing systemic exposure and toxicity, allowing dosing to be
optimized to deliver the best outcomes for patients.
About AVA6000: FAP-enabled doxorubicin
The lead
pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin,
is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple
patients.To register for news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/.
About Avacta Group plc - https://avacta.com/
Avacta Group is a UK-based
life sciences company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics. Its clinical
stage oncology biotech division Avacta Therapeutics is harnessing
the proprietary pre|CISION® platform technology to develop
novel, highly targeted cancer drugs. Avacta
Diagnostics focuses on supporting healthcare professionals and
broadening access to diagnostics. To register for news alerts by
email go to https://avacta.com/investors/investor-news-email-alerts/.
